EXPERIMENTAL STUDY

Effect of long-term ovariectomy and estrogen replacement on the expression of estrogen receptor gene in female rats

M K Mohamed and A A Abdel-Rahman

Department of Pharmacology, School of Medicine, East Carolina University, Greenville, North Carolina, USA

(Correspondence should be addressed to A A Abdel-Rahman; Email: rahman@brody.med.ecu.edu)

Abstract

Objective: Estrogen exerts a wide variety of actions involving many target tissues. We studied the effects of long-term ovariectomy (OVX) and OVX with 17β-estradiol treatment (OVXE2) on the level of estrogen receptor (ER) gene expression in target tissues of female rats.

Design: Three groups of Sprague–Dawley female rats were utilized in this study: sham operated (SO), OVX and OVXE2.

Methods: SO and OVX were performed 2 weeks before starting the 17β-estradiol treatment. All groups were maintained on liquid diet for 12 weeks from the time of estradiol treatment. Total RNA was prepared from the tissues of the rats and relative quantitative reverse transcription PCR was utilized to compare the ERα-subtype (ERα) mRNA level in the three groups for each target tissue.

Results: Following long-term OVX, the levels of ERα expression showed a significant increase in the uterus, kidney and cerebral cortex and no significant change in the liver, cerebellum, brainstem, heart and thoracic and abdominal aorta compared with their SO levels. On the other hand, a 12-week treatment of OVX rats with 17β-estradiol restored the previously upregulated ERα mRNA to near SO levels except for the liver where the 17β-estradiol treatment resulted in a significant increase in the ERα mRNA level compared with that in SO rats.

Conclusions: We conclude that the regulation of ERs by its ligand is tissue specific.

Introduction

Estrogen plays an important role in growth, differentiation and function of many target tissues, including tissues of the female and male reproductive system (1). Estrogen also plays an important role in the maintenance of bone mass and in cardiovascular protection (2, 3). To produce its action, estrogen binds to intranuclear receptors known as estrogen receptors (ERs). These receptors are cis-acting transcription factors, members of the steroid receptors superfamily (4). ERs contain three main structural and functional domains; a highly conserved DNA-binding domain located in the middle of the molecule, a less conserved C-terminal ligand-binding domain and a hypervariable N-terminal transactivation domain (5). After binding to its ligand, two molecules of ER dimerize and bind to the specific DNA sequence, estrogen response element, inside the nucleus, followed by activation of target gene transcription (6).

The autoregulation of ER by its ligand has been the subject of many previous studies. In 2-week ovariectomized (OVX) adult female rats, a single injection of estradiol resulted in more than an 80% decrease in uterine cytosolic ER binding within 1 h (7). This decrease in binding was explained in part by nuclear translocation of the receptor after hormone binding. However, this cannot explain the 50% reduction in the total cellular ER within 1 h of estradiol injection (8). Estrogen in low doses was shown to upregulate while in high doses it downregulates its receptor in the rat uterus (9, 10). In another study, estrogen deficiency downregulated, whereas estrogen and growth hormone administration upregulated intestinal ERs and prevented the OVX-induced decrease in receptor binding affinity (11). Zou & Ing (12) reported that estradiol upregulates ER mRNA in endometrium, but downregulates it in the liver. In contrast, estrogen upregulates ER in the liver of Xenopus laevis (13). In rat bone, there was a sharp decrease in ER mRNA level when estrogen was reduced after OVX and the expression of bone ER mRNA increased during estradiol therapy (14). In this study we investigated the long-term effects of OVX and estrogen replacement on ER gene expression in different rat tissues including the heart, thoracic and abdominal aorta, cerebral cortex, brain stem and cerebellum. The choice of these tissues was based on our interest in studying the effects of estrogen and consequent changes in ERs in cardiovascular tissues and brain areas that control blood pressure. For
Materials and methods

**OVX**
Female Sprague–Dawley rats (9–10 weeks old; Harlan, Indianapolis, IN, USA) were employed in this study. Bilateral OVX was performed as described in our previous studies and others (15–17). Briefly, the rat was anesthetized using methohexital (50 mg/kg i.p.). The lower part of the back skin was shaved and a single 2–3 cm incision was made in the skin to expose the back muscles. A small 1–2 cm incision was made in the muscles overlying the ovaries on both sides and the ovaries were isolated, tied off with sterile suture and removed. The muscles and the skin were sutured separately, and the rats were allowed to recover for approximately 2 weeks before the time of the experiment. Sham operation (SO) was performed by exposing the ovaries without isolation. Following OVX or SO, each rat received an s.c. injection of buprenorphine hydrochloride (Buprenex; 30 µg/kg) to control pain and an i.m. injection of 50 000 U/kg of penicillin G benzathine and penicillin G procaine in an aqueous suspension (Duragen) and was housed in a separate cage. All surgical procedure and post-operative care were done in accordance with the institutional guidelines for animal care and use.

Two weeks after OVX, 17β-estradiol, 1.7 mg/pellet, 120-day release (Innovative Research of America, Sarasota, FL, USA) was implanted s.c. in some of the OVX rats to form a 17β-estradiol-treated OVX group (OVXE2). Rats of the SO and OVX groups received control pellets s.c. (placebo for 17β-estradiol).

**Diets**
The three groups of rats were maintained on Leiber DeCarli high protein liquid diet #710029 (Dyets, Bethlehem, PA, USA). The daily intake was adjusted so that each rat in the three groups consumed an equal amount of the liquid diet when compared with other rats.

**Total RNA preparation**
At the end of the study, rats from different groups were killed by decapitation, tissues were immediately removed, frozen in liquid nitrogen and stored at −80°C until used. A total of 33 rats, divided into three groups (n = 11 each), were employed in the present study. The sample size varied between four and eight due to the loss of some samples. Thawed tissues (100–200 mg) were homogenized in 1–2 ml TRIzol reagent (Life Technologies, Gaithersburg, MD, USA) and total RNA was prepared according to the manufacturer’s instructions.

**DNase I digestion of RNA preparation**
To eliminate residual genomic DNA from the RNA sample and avoid artificial amplification in reverse transcription PCR (RT-PCR), 3 µg total RNA from each sample were digested with 2 units of amplification grade DNase I (Life Technologies) in a reaction mix containing 20 mmol/l Tris–HCl (pH 8.4), 50 mmol/l KCl, and 2 mmol/l MgCl2 in diethyl pyrocarbonate-treated H2O to a final volume of 10 µl. The reaction was incubated at room temperature for 15 min and stopped by the addition of 1 µl 25 mmol/l EDTA and incubation at 65°C for another 15 min.

**Relative quantitative RT-PCR**
The previously DNase I-digested RNA samples were used for the first-strand cDNA synthesis using random hexamers and the SuperScript Preamplification system kit (Life Technologies) according to the manufacturer’s instruction manual. Briefly, 100 ng of the random hexamers were incubated with the DNase I-digested RNA samples at 70°C for 10 min. A reaction mix containing 2 µl 10 × PCR buffer, 2 µl 25 mmol/l MgCl2, 1 µl 10 mmol/l dNTP mix and 2 µl 0.1 mol/l dithiothreitol was then added to each RNA/primer and incubated at room temperature for 5 min. One micro-liter (200 units) of SuperScript II (Life Technologies) reverse transcriptase enzyme was then added to each tube, mixed, incubated at room temperature for 10 min and at 42°C for 50 min. The reaction was stopped by incubation at 70°C for 15 min. The RNA hybrid with the newly synthesized cDNA in each sample was then digested by incubation with 1 µl (1 unit) of E. coli RNase H at 37°C for 20 min.

The relative quantitative PCR was then assembled for each sample by adding 2 µl (1/10) of the cDNA sample reaction to 5 µl 10 × PCR buffer, 3 µl 25 mmol/l MgCl2, 1 µl 10 mmol/l dNTPs, 5 µM of ERα-specific primers, 2.5 µl 18S primers/competimers (4:6) (Ambion Inc., Austin, TX, USA), 1.5 units of thermophilic polymerase and double-distilled H2O to a final volume of 50 µl. The PCR mixture was supplemented with 1–2 µCi [α-32P]dCTP (10 mCi/ml, ~3000 Ci/mmol; Amersham, Arlington Heights, IL, USA) for labeling and better detection of the PCR products. The ERα-specific primers used for PCR amplification were S1 (sense, −16 relative to ATG: 5′- GCGGCTGCACTGACATG) and AS2 (antisense, +169 relative to ATG: 5′- CCTCGGGTAT TTGAACAGG) (18) allowing the amplification of a 185 bp fragment corresponding to the 5′ non-coding region and to the first part (N-terminal) of the coding region of rat ER gene (19). The amplification was performed in a GeneAmp 2400 (Perkin Elmer, Foster City, CA, USA), and consisted of 25 cycles (30 s of
denaturation at 94°C, 30 s of annealing at 55°C, and 45 s elongation at 72°C, with a final elongation at 72°C for 9 min. Four percent non-denaturing PAGE was utilized to analyze the PCR products. The gel was then dried and exposed to X-ray film.

Estradiol measurement
Weekly blood samples were collected from the rats under study. EDTA plasma was separated by centrifugation and stored at −20°C until the time of measurement. The estradiol level in the samples was measured using an Estradiol DSL-4400 Radioimmunoassay kit (Diagnostic Systems Laboratories, Inc., Webster, TX, USA) according to manufacturer’s instructions.

NIH image analysis
Analysis of the bands was performed on a power Macintosh 7300/180 computer using the public domain NIH Image program (developed at the US National Institutes of Health). A gel-plotting macro was used to outline the bands and the area underneath the curve was calculated. The intensity was calculated on the uncalibrated OD setting. The area representing the ERα band over the area representing the 18S ribosomal RNA band (ERα/18S RNA) for tissues from the SO rats was taken as a control and representing a 100% expression level. The percentage ERα/18S RNA of OVX or OVXE2 rats compared with that of the SO rats represents the response of ERα expression in the tissues examined elicited by OVX and OVXE2, respectively.

Statistical analysis
Values are expressed as mean±S.E.M. An ANOVA followed by a Newman–Keuls post-hoc analysis was used for multiple comparisons. Student’s t-test was used in the analysis of paired and unpaired data with the level of significance set at P<0.05.

Results

Plasma estradiol level
During the first 6 weeks, the plasma estradiol level was very high in the OVXE2 group, which had received the s.c. slow release pellets. However, plasma estradiol level declined to physiological values by weeks 10–12 (34.7±5.7 pg/ml in weeks 10–12). The estradiol level was low in OVX rats throughout the study, with an average of 8.8±1.1 pg/ml during weeks 10–12. In the SO group, the level of estradiol was fluctuating with increases and decreases according to the number of rats that happened to be in the proestrus phase of the estrous cycle. In general, the estradiol level in the SO group was higher than in OVX but lower than in the OVXE2 groups, with a 10–12 weeks average level of 13.8±2.4 pg/ml.

Gain in body weight following OVX and OVXE2
OVX rats gained an average of 40 g in body weight compared with their age- and weight-matched SO rats. As shown in Fig. 1, following s.c. implantation of the 17β-estradiol pellets, there was a sharp decrease in body weight within 1 week in the OVXE2 rats, which maintained an average body weight comparable with, but slightly lower than, that of the SO rats. Following the rapid weight gain that occurred early after OVX, the increase in weight was gradual (Fig. 1). The difference in body weight, between the OVX group on the one hand and the SO and OVXE2 groups on the other hand, was maintained throughout the whole period of the study (Fig. 1).

![Figure 1](https://www.eje.org)

**Figure 1** The effect of OVX and estrogen replacement on gain in body weight. OVX (n=11) or SO (n=11) was performed 2 weeks before starting estrogen treatment (OVXE2) (n=11). * and #P<0.05 compared with SO and OVXE2 respectively.
Uterine ERα gene expression

The uterus, as the main target organ for estrogen, was the first tissue to be examined and was taken as a reference for the long-term effects of OVX or OVXE2 on ERα gene expression. After total RNA extraction from the uterine tissue, RT-PCR was used to amplify the ERα message using gene-specific primers. 18S ribosomal RNA was used as an internal standard and for adjustment of sample-to-sample variations. Compared with the SO group (taken as 100%), the ERα gene expression was significantly \((P < 0.001)\) higher \((212 \pm 23.9\%)\) and lower \((77 \pm 6.4\%)\) in the OVX and OVXE2 groups respectively (Fig. 2A and B). This finding shows that there is upregulation of the ERα subtype in response to long-term OVX in rat uterine tissue and that the chronic administration of estrogen downregulates the receptor at the transcription level.

Variable expression of ERα in liver and kidney

Estrogen deficiency following OVX resulted in a significant increase \((P < 0.025)\) in the level of ERα gene expression in the kidney \((273.5 \pm 61.2\%\) of control), but no significant change \((103.0 \pm 13.1\%\) of control) was detected in the liver (Fig. 3A and B). Treatment of OVX rats with 17β-estradiol reduced the gene expression of ERα in the kidney to control level \((118.0 \pm 27.2\%\) of control). On the other hand, there was a significant \((P < 0.05)\) increase \((137.7 \pm 13.9\%\) of control) in the gene expression of ERα in the liver of OVXE2 rats.

Expression of ERα in cardiovascular tissues

The effects of estrogen depletion and replacement were also studied in cardiovascular tissues (the heart and

---

**Figure 2** The expression of ER in rat uterus. (A) A 4% non-denaturing PAGE showing the \([\alpha-32P]dCTP\)-labeled RT-PCR products of ER of SO, OVX and OVXE2 female rats in relation to 18S ribosomal RNA (the internal standard). (B) A bar graph representing the changes in ER expression level in OVX \((n=8)\) and OVXE2 \((n=8)\) rats in arbitrary densitometric units (ADU) as percent of SO rat levels (taken as 100%). *\(P<0.001\) and < 0.005 for OVX and OVXE2 respectively compared with SO \((n=8)\). #\(P<0.001\) for OVXE2 compared with OVX.

**Figure 3** The expression of ER in female rat kidney and liver. (A) A 4% non-denaturing PAGE showing RT-PCR products of ER of SO, OVX and OVXE2 rats in relation to 18S ribosomal RNA (the internal standard) in both liver and kidney. (B) A bar graph representing the changes in ER expression level in kidney and liver of OVX \((n=5)\) and OVXE2 \((n=5)\) rats in arbitrary densitometric units (ADU) as percent of SO rat \((n=5)\) levels (taken as 100%). *\(P<0.02\) for OVX compared with SO. #\(P<0.05\) for OVXE2 compared with OVX.
thoracic and abdominal aorta (Fig. 4A and B). Following long-term OVX, there was a non-significant reduction in the expression level of ERα in the heart (76.0 ± 10.7% of SO level) and abdominal aorta (96.1 ± 12.3% of SO level) and a non-significant increase (151.0 ± 20.2% of SO level) in thoracic aorta. The latter did not achieve statistical significance because of variability of the responses. On the other hand, long-term treatment of OVX rats with 17β-estradiol reversed the effects of OVX on the expression level of ERα in the heart (93.0 ± 34.7% of SO level) and thoracic aorta (113.0 ± 17.1% of SO level) but had no effect on the expression level in the abdominal aorta (97.1 ± 12.1% of SO level).

Expression of ERα in brain tissues

As shown in Fig. 5A and B, long-term OVX resulted in a significant (P < 0.05) increase in the level of expression of ERα in cerebral cortex (123 ± 8.0%) and a non-significant increase (129 ± 15.9%) in brainstem compared with their SO levels respectively. The latter did not achieve statistical significance because of the inter-individual variability of the responses. In cerebellum, there was a non-significant decrease in the ERα expression level (87 ± 23.5% compared with SO rat levels). 17β-Estradiol had no significant effect on the ERα expression in cerebral cortex, brainstem and cerebellum. Comparison of the level of ERα expression in the three brain tissues of the SO group revealed tissue-dependent distribution of ERα (Fig. 6). The cerebral cortex and brainstem contained higher levels of ERα when compared with the cerebellum in the same group of rats (Fig. 5A and B).

Discussion

Post-menopausal women are at increased risk for many health problems such as cardiovascular diseases and osteoporosis compared with premenopausal women or even with age-matched males (20). The main difference is the deficiency of the ovarian hormones, especially estrogen, in post-menopausal women. Previous studies investigated the changes in ER gene expression in one or more tissues, but this was done under estrogen depletion or treatment for a short
The existence of ER in mammalian livers was reported in previous studies (24). The liver contains only ERα with no ERβ detected (25). In our study, using the relative quantitative RT-PCR, we detected the presence of ERα in female rat liver. No significant changes were seen in the ER mRNA levels after long-term estrogen deprivation (OVX) for 12 weeks compared with those in SO rats. In OVXE2 rats, there was a significant increase in the ER mRNA levels compared with those in SO rats. In a previous study (26), androgens showed a negative regulatory influence, while estrogens and adrenal and thyroid hormones did not influence the regulation of hepatic ER mRNA in rats. Our results do not support the reported finding and partially agree with the reported findings by Shupnik et al. (27) where liver ER mRNA declined 1.5- to 3-fold after OVX and returned to intact levels after 1–3 days of estradiol replacement. This may be explained by the difference between the studies in the duration of OVX (3–4 weeks in their study compared with 12 weeks in ours) and estrogen treatment (daily injection with 17β-estradiol for a maximum of 7 days compared with 12 weeks of slow release pellets of 17β-estradiol in our study). We also used a more sensitive technique, RT-PCR, which is not dependent on detecting full-length receptor but can still detect partially degraded mRNA so long as this degradation does not involve the sequence of interest. Using the hydroxyapatite assay, Spano et al. (28) reported an increase in the concentration of hepatic ER in gonadectomized male and female rats compared with that in intact rats.

To our knowledge, this is the first study to investigate the effect of estrogen deprivation and replacement on the ERα gene expression in the kidney. The ERα mRNA level in the kidney showed variation similar to that seen in the uterus, with upregulation and increased expression of ERα with estrogen deprivation in ovariectomized rats. With estrogen replacement, the ERα expression decreased to levels similar to those seen in the SO control group.

The existence of functional ERs in human vascular smooth muscle cells (29) and myocardial and myogenic cells (30, 31) has been reported. In the present study, the changes in ERα expression were non-significant in the heart, thoracic aorta and abdominal aorta following OVX or 17β-estradiol replacement. It seems unlikely that the mechanisms by which estrogen produces its cardiovascular protective effects may involve changes in the ERα gene expression in the tissues examined. A possible mechanism may involve reduction of circulating levels of both angiotensin-converting enzymes (32) by estrogen treatment. Direct effects on cardiac cells through activation of other genes or other subtypes of the ER may be another mechanism of action for estrogen.

Three different areas of the brain, cerebral cortex, cerebellum and brainstem, were examined for the expression of ERα and their response to estrogen.
deprivation or treatment. The expression level of ERα was higher in cerebral cortex and brainstem compared with that in cerebellum. The ERα expression was significantly upregulated following OVX in the cerebral cortex. No significant changes were observed in the brainstem or cerebellum.

It is important to comment on the relevance of estrogen-mediated changes in ER gene expression to the biological actions of estrogen. For example, the findings on brainstem ERα expression are surprising, given our recent findings that estradiol enhances baroreflex sensitivity via a central site of action (15). It is possible that estradiol action involves non-transcription pathways or the other ER receptor isoform, ERβ, which is expressed in the brainstem (33). Recent evidence suggests that the differential distribution of ER proteins denoting the ERα and ERβ subtypes may explain specific cellular actions of estradiol in some tissues (30, 31, 34). Two recent findings suggest that some biological effects of estrogen may be dependent on one, but not the other, ER isoform. First, the induction of galanin gene expression in the pituitary of the mouse by estrogen is dependent on the presence of functional ERα (35). Second, the presence of functional ERβ in the rat cortex is essential for the expression of the neuroprotective action of estrogen observed in a model of cerebral ischemia (36). Taken together, the present findings suggest that brainstem ERα does not seem to play a crucial role in estrogen-evoked enhancement of baroreflex activity. It is possible that this favorable effect of estrogen is dependent on ERβ or may involve a non-transcriptional action of estrogen. Future studies are warranted to address this issue.

In conclusion, our results show that the regulation of ER gene expression by estrogen deprivation or treatment is tissue specific. Knowledge of the expression level of ER in different tissues may be valuable for the understanding of the mechanism of action underlying the different responses to estrogen agonists and/or antagonists in a tissue-specific manner.

Acknowledgements

This work was supported by Grant AA10257 from the National Institute on Alcohol Abuse and Alcoholism to AAR. We also would like to thank Ms Swarooparani Vadlamudi for her technical assistance.

References


www.eje.org

Downloaded from Bioscientifica.com at 01/08/2019 07:39:21AM via free access


Received 21 June 1999
Accepted 26 October 1999